Curevac
Pioneering mRNA technology to create vaccines and therapies for infectious diseases, cancer, and more.
CVAC | F
Overview
Corporate Details
- ISIN(s):
- NL0015436031
- LEI:
- 724500BUT8GAG9LMYN56
- Country:
- Germany
- Address:
- Friedrich-Miescher-Strasse 15, 72076 Tübingen
- Website:
- https://www.curevac.com/en/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
CureVac is a global biopharmaceutical company and a pioneer in the field of messenger RNA (mRNA) technology, with over 20 years of experience since its founding in 2000. The company leverages its proprietary mRNA platform to develop a new class of transformative medicines. Its core focus is on creating prophylactic vaccines for infectious diseases and therapeutic treatments for cancer and rare diseases. By providing the body with specific mRNA-based information, CureVac's approach aims to enable the patient's own body to produce proteins and fight a wide range of illnesses.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Curevac and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-15 13:27 |
Earnings Release
CureVac Announces Financial Results for the Second Quarter and First Half of 20…
|
English | 25.8 KB | |
| 2025-08-08 02:15 |
Legal Proceedings Report
CureVac Announces Resolution of Patent Litigation with Pfizer/BioNTech
|
English | 11.5 KB | |
| 2025-06-24 22:09 |
Declaration of Voting Results & Voting Rights Announcements
CureVac Announces Voting Results of General Meeting
|
English | 10.0 KB | |
| 2025-05-20 13:00 |
Earnings Release
CureVac Announces Financial Results for the First Quarter of 2025 and Provides …
|
English | 23.3 KB | |
| 2025-05-15 22:10 |
Legal Proceedings Report
CureVac Receives Additional Positive Validity Decision from European Patent Off…
|
English | 12.1 KB | |
| 2025-04-10 13:12 |
Earnings Release
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 a…
|
English | 39.8 KB | |
| 2025-04-09 13:00 |
Report Publication Announcement
CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Busin…
|
English | 10.4 KB | |
| 2025-04-07 13:00 |
Regulatory News Service
CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for …
|
English | 14.7 KB | |
| 2025-03-27 21:05 |
Legal Proceedings Report
CureVac Receives Positive Validity Decision from European Patent Office in Liti…
|
English | 11.9 KB | |
| 2025-02-19 13:03 |
Environmental & Social Information
CureVac Earns Repeat Recognition by LexisNexis as One of the Worlds Top Innovat…
|
English | 12.2 KB | |
| 2025-02-18 13:03 |
Regulatory News Service
CureVac Earns Repeat Recognition by LexisNexis as One of the Worlds Top Innovat…
|
English | 12.2 KB | |
| 2024-04-25 00:00 |
Foreign Filer Report
|
English | 4.3 MB |
Automate Your Workflow. Get a real-time feed of all Curevac filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Curevac via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
